IceCure Medical Ltd. (NASDAQ: ICCM) received a 180-day extension from NASDAQ to regain compliance with the exchange's minimum bid price requirement, according to a company statement. The extension period runs until November 9, 2026.

NASDAQ initially notified IceCure on November 12, 2025, that its ordinary shares failed to meet the minimum $1.00 bid price per share requirement for 30 consecutive business days. The company was given 180 calendar days until May 11, 2026, to regain compliance but did not meet the requirement during that period.

IceCure submitted a written request for an additional compliance period, which NASDAQ granted on May 12, 2026. The extension was based on the company meeting continued listing requirements for market value of publicly held shares and other applicable requirements for initial listing on the NASDAQ Capital Market, except for the bid price requirement.

To regain compliance, IceCure's ordinary shares must maintain a closing bid price of at least $1.00 per share for a minimum of 10 consecutive business days before the November deadline. NASDAQ may require the company to maintain the $1.00 bid price for up to 20 consecutive business days to demonstrate long-term compliance ability.

The company indicated it may effect a reverse share split if necessary to cure the deficiency. IceCure's ordinary shares continue to trade on the NASDAQ Capital Market under the symbol "ICCM" with no immediate effect on listing or trading.

IceCure Medical develops cryoablation technology systems that destroy tumors by freezing, focusing on breast, kidney, bone and lung cancer treatments. The company markets its ProSense system in the United States, Europe and Asia.